Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

Sponsor
Alpha Tau Medical LTD.
Study ID
NCT06026943
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • DaRT seeds insertion — DEVICE
    An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms

Study Details

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer

Key Dates

First listed
Sep 7, 2023
Start date
May 6, 2026
Status verified
Aug 2025
Primary completion
Jan 31, 2027
Completion
Jan 31, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DaRT Seeds
    Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Primary Outcome Measure

Feasibility- DaRT seed placement [ Time Frame: Immediately following the insertion procedure ]

Central Contacts

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies